

## **Ajanta Listed on Forbes Asia's '200 Best under Billion' 2014 Recognition for Third Consecutive Year**

**Mumbai - (19<sup>th</sup> August, 2014) - Ajanta Pharma Limited**, a specialty focused pharmaceutical formulation company, announced today that the company has been listed on Forbes Asia's 'Best Under a Billion' 2014 list. This is the third consecutive listing of the company since 2012.

The "Best Under A Billion" list is published by Forbes Asia to recognize 200 small and mid-sized publicly listed companies in Asia Pacific region with annual revenue under \$1 billion. The companies were selected based on three stringent categories of profitability, growth, and modest indebtedness from a universe of 17,000 stock-traded companies across Asia-Pacific region. The qualifying companies have comparatively produced the highest sales and earnings per share growth for both the most recent fiscal one and three-year periods, and the strongest five-year average return on equity.

Commenting on the listing, Mr. Yogesh M. Agrawal, Managing Director, Ajanta Pharma Limited, said "We are pleased to receive this recognition for the third consecutive year from Forbes. Inclusion in this list yet another year bears testimony to Ajanta's consistent performance which is the outcome of our commitment to quality, investment in R&D and manufacturing facilities, intelligent product selection and aggressive marketing in India and other geographies we operate."

For the complete list of companies on Forbes Asia's 'Best under a Billion', please visit <http://www.forbes.com/asia200/>

### **About Ajanta Pharma Limited**

Ajanta Pharma - a speciality pharmaceutical formulation company has leading brands in therapeutic segments of Ophthalmology, Dermatology, Cardiology and Pain management. Many of company's products are first in the market place and are leading in their sub therapeutic segments. Company has a well-established branded generic business in emerging markets. It has recently entered the regulated markets of USA and is building a portfolio of ANDAs for this market.

Company's state of the art R&D centre for formulation development is located at Mumbai, having a team of 350+ people. Company has world class manufacturing facilities - 4 located in India and 1 at Mauritius. One of the manufacturing facilities in India is approved by US



BSE: 532331  
Reuters: AJPH.NS

NSE: AJANTPHARM  
Bloomberg: AJP:IN

FDA, UK MHRA, pre-qualification from World Health Organisation (WHO), apart from having the approval from FDAs of many other countries. Company is setting up two more manufacturing facilities in India, one for regulated markets and another for domestic and emerging markets.

For last 5 years, company has been able to achieve outstanding performance with its consolidated revenue showing a CAGR of 31% and net profit of 62%.

For more details visit [www.ajantapharma.com](http://www.ajantapharma.com)

